(NASDAQ: PYXS) Pyxis Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.98%.
Pyxis Oncology's earnings in 2026 is -$79,621,000.On average, 10 Wall Street analysts forecast PYXS's earnings for 2026 to be -$82,993,793, with the lowest PYXS earnings forecast at -$96,056,409, and the highest PYXS earnings forecast at -$62,674,168. On average, 10 Wall Street analysts forecast PYXS's earnings for 2027 to be -$84,595,990, with the lowest PYXS earnings forecast at -$111,450,064, and the highest PYXS earnings forecast at -$56,076,887.
In 2028, PYXS is forecast to generate -$84,118,472 in earnings, with the lowest earnings forecast at -$123,149,242 and the highest earnings forecast at -$22,430,755.